New hope for brain cancer: targeted drug combo shows promise
NCT ID NCT07405255
First seen Feb 13, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tests a new drug called zanubrutinib combined with chemotherapy for people newly diagnosed with central nervous system lymphoma. About 19 participants will receive the treatment, and those who respond well will continue zanubrutinib for 2 years to keep the disease under control. The goal is to see if this approach improves remission rates and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.